Recently, Shanghai Aidu Biotechnology (Aidu Biotech) successfully completed the production and shipment of 200 kg of β-Nicotinamide Adenine Dinucleotide (NAD⁺) to the United States market.
The entire batch was manufactured and released at Aidu Biotech’s self-owned production facility, demonstrating the company’s strong in-house manufacturing capability and its commitment to reliable global supply.
Aidu Biotech sincerely appreciates the continued trust and support of our international partners. This shipment further strengthens our long-term collaboration with customers in the U.S. and other mature health ingredient markets.
In-House Manufacturing: The Foundation of Stable NAD⁺ Supply
Unlike suppliers that rely on outsourced or contract manufacturing, Aidu Biotech produces NAD⁺ entirely within its own facility, covering the full manufacturing cycle—from process control and quality inspection to batch release.
This in-house production model enables tighter control over:
- Product consistency across batches
- Impurity profile and quality parameters
- Production scheduling and delivery timelines
As a result, Aidu Biotech is able to meet the stringent expectations of U.S. customers for long-term supply reliability, traceability, and manufacturing transparency.
From Production Capability to Long-Term Supply Assurance
As the NAD⁺ market matures, customers are no longer focused solely on price or short-term availability. Instead, they increasingly prioritize whether a supplier has real manufacturing capacity and sustainable supply capability.
With its self-owned factory, Aidu Biotech offers clear advantages:
- Scalable production capacity, supporting both mid- and large-volume orders
- Unified quality system, ensuring batch-to-batch consistency
- Reduced supply-chain risk, avoiding uncertainties associated with third-party manufacturing
These strengths have enabled Aidu Biotech’s NAD⁺ products to gain stable traction in the U.S. and other international markets.
NAD⁺ Market Outlook for 2026: Manufacturing Origin Matters More Than Ever
Based on current market dynamics and customer feedback, manufacturing origin is expected to become a key differentiator for NAD⁺ products by 2026:
1. In-house production as a purchasing criterionBrands and formulators increasingly favor NAD⁺ suppliers with self-owned facilities that can support audits and long-term partnerships.
2. Higher expectations for consistency and stabilityAs NAD⁺ is widely used in high-value formulations, consistent quality and reliable supply are becoming non-negotiable requirements.
3. Expansion from single products to integrated ingredient portfoliosManufacturers with in-house capabilities are better positioned to support product upgrades and future NAD⁺-related innovations.
Committed to Long-Term Value in NAD⁺ Manufacturing
Looking ahead, Aidu Biotech will continue to invest in its in-house manufacturing platform, strengthening process optimization, quality management, and global supply capabilities for β-Nicotinamide Adenine Dinucleotide (NAD⁺) and other cell-energy-related ingredients.
For more information about Aidu Biotech’s NAD⁺ specifications, production capacity, or partnership opportunities, please feel free to contact us.